Results 231 to 240 of about 157,671 (305)
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer. [PDF]
NPJ Breast CancerVan Mackelenbergh MT, Pfarr N, Weber K, Untch M, Solbach C, Schneeweiss A, Jank P, Blohmer J, Treue D, Schmatloch S, Lehmann A, Hanusch C, Link T, Sers C, Bjelic-Radisic V, Hummel M, Huober J, Schmitt WD, Fasching PA, Aktas B, Rhiem K, Reinisch M, Nekljudova V, Denkert C, Loibl S. +24 moreeuropepmc +1 more sourcePlasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial
International Journal of Cancer, EarlyView.Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O. Goetze, Salah E. Al‐Batran, Sonja Loges, Melanie Janning +17 morewiley +1 more sourceImpact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision‐Making in Dutch Breast Cancer Patients: A Population‐Based Study
International Journal of Cancer, EarlyView.To avoid unnecessary treatment in breast cancer, several gene expression profiling tests have been developed to help clinicians identify patients who may not benefit from chemotherapy. This study examined the effect of reimbursement availability on the implementation of gene expression profiles using population‐based data from the Netherlands Cancer ...Joyce Meijer, Nienke Hermanns, Rhodé Bijlsma, Hedwig M. Blommestein, Desiree H. J. G. van den Bongard, Thijs van Dalen, Paul J. van Diest, Caroline A. Drukker, Cristina Guerrero Paez, Aafke H. Honkoop, Agnes Jager, Linetta B. Koppert, Sabine C. Linn, Marissa C. van Maaren, Ester J. Siemerink, Laura J. van ’t, José H. Volders, Marie Jeanne Vrancken Peeters, Sabine Siesling +18 morewiley +1 more sourceAnalysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project. [PDF]
ESMO OpenSánchez-Bayona R, de Nicolás-Hernández J, Saura C, Gion M, Cejalvo JM, Llabrés E, Cortés J, Falcón A, Pernas S, López de Sa A, Vidal M, Hinojo C, Curiel T, Cruz J, Martínez V, Cantos B, Echarri MJ, Gallegos I, Bueno C, Vargas AM, Escrivá-de-Romaní S, Fullana B, Cobos MA, Arenas A, Joval-Ramentol L, Ortiz P, Pascual T, Valdivia C, Villacampa G, Ciruelos E, Rodriguez-Antona C. +30 moreeuropepmc +1 more sourceHow enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study. [PDF]
Future OncolGupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Homet Moreno B, Beaumont JL, Purnajo I, McManus S, Powles T. +24 moreeuropepmc +1 more sourceBaseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study. [PDF]
ESMO Gastrointest OncolVandeputte H, Casadei-Gardini A, Peeters F, Rimini M, Nichetti F, Saborowski A, Antonuzzo L, Passeri L, Satake T, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Corallo S, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Lancianese A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, De Rosa A, Lanzetta I, Balsano R, Lavacchi D, Camera S, Ikeda M, Niger M, Tesini G, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Ferrara M, Lo Prinzi F, Himmelsbach V, Landriscina M, Djaballah SA, Persano M, Salani F, Vogel A, Lonardi S, Fornaro L, Rimassa L, Dekervel J. +73 moreeuropepmc +1 more sourceBenralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis. [PDF]
ERJ Open ResMukherjee M, Tan NS, Huang C, Kim B, Radford K, Ju X, Venegas Garrido C, Kjarsgaard M, Rodríguez-Suárez E, Wechsler ME, Walker B, Börjesson Sjö L, Necander S, Ashkar A, Weidner J, Sehmi R, McCrae C, Khalidi N, Nair P. +18 moreeuropepmc +1 more sourceDurvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD. [PDF]
JTO Clin Res RepCho BC, Nishio M, Ahn MJ, García-Campelo R, Ponce S, Baik C, Salgia R, Kim SW, Lee JS, Yoshida T, Yu HA, Goldberg SB, Johannes de Langen A, Le X, Piotrowska Z, Riess JW, Tanaka K, Ambrose H, Cosaert J, Fraenkel PG, Tang KH, Lehman JM, Smith P, Goldman JW. +23 moreeuropepmc +1 more source
